Human Immunodeficiency Virus Type-1 (HIV-1)- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s ‘Human Immunodeficiency Virus Type-1 (HIV-1)―Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the HIV-1, historical and forecasted epidemiology as well as the HIV-1 market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The HIV-1 market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM HIV-1 market size from 2018 to 2030. The Report also covers current HIV-1 treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018–2030

HIV-1 Disease Understanding and Treatment Algorithm

HIV-1 Overview

HIV is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. HIV is a retrovirus built of RNA rather than the typical DNA. It attacks the cells (T lymphocytes and other white blood cells with CD4 receptors on their surfaces) that are a part of the body’s immune system.

It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV) or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).

HIV is classified into two broad categories HIV-1 and HIV-2. HIV-1 is the most common; more than 90% of people living with HIV have HIV-1. HIV-1 is further subcategorized into groups: M, N, O, and P. Among these groups, group M is most common, further divided into nine subtypes (from A to K except E and I). HIV-1 is more easily transmitted from one person to another or from mother to child. HIV-1 is spread across all over the world.

HIV-1 Diagnosis

HIV-1 can be diagnosed via several methods, including antibody tests, antigen/antibody tests, and Nucleic Acid Tests (NATs). Additional tests during treatment include viral load, CD4 count, and drug resistance testing. The diagnosis of HIV infection is most commonly accomplished using tests to detect antibodies to HIV in blood or oral fluid using a screening test, followed by a supplemental test for confirmation. Enzyme immunoassays (EIAs) are the most commonly used methods to perform antibody tests.

Continued in the report…..

HIV-1 Treatment

The treatment for HIV is called antiretroviral therapy (ART). ART involves taking a combination of HIV medicines (called an HIV treatment regimen) every day. The main goal of HIV treatment is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test. People with HIV who maintain an undetectable viral load have effectively no risk of transmitting HIV to their HIV-negative partners through intercourse. There is no effective cure for HIV. But proper medical care can control HIV.

To date, many drugs have been approved in ART. Reverse transcriptase inhibitors were the first class that came into existence. Reverse transcriptase inhibitors are approved for two main viral infections. The first approved use is for the treatment of HIV, specifically the HIV-1 strain. The first class is the nucleoside/nucleotide reverse transcriptase inhibitors, and the second class is the non-nucleoside reverse transcriptase inhibitors. Other than reverse transcriptase inhibitors, there are many approved classes of ART. Each class has a significant role in the treatment of HIV-1.

HIV-1 Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of HIV, total diagnosed prevalent cases of HIV, type-specific diagnosed prevalent cases of HIV, gender-specific diagnosed prevalent cases of HIV-1, diagnosed prevalent cases of HIV-1 by route of transmission, and age-specific diagnosed prevalent cases of HIV-1 scenario of HIV-1 in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Key Findings
Total prevalent cases of HIV in the 7MM was found to be 1,926,925 in 2020. These cases are expected to increase by 2030 at a CAGR of 1.26% during study period (2018–2030).
The diagnosed prevalent cases of HIV in the 7MM was found to be 1,597,714 in 2020 which is expected to increase at a CAGR of 1.75% for the study period of 2018-2030.
Among 7MM, the United States has the highest diagnosed prevalent cases of HIV with 991,073 cases in 2020.
The diagnosed prevalent cases HIV were further divided into two broad categories, HIV-1 and HIV-2. There were total 990,974 cases of HIV-1 and 99 cases of HIV-2 in 2020 in the United States.
Assessments as per DelveInsight’s analysts show that the majority of cases of HIV-1 are occupied by males as compared to females. There was a total of 723,411 male and 267,563 female cases of HIV-1 in 2020 in the United States.
There are a plethora of modes of transmission of HIV1, among which the most common types of routes are male-to-male sexual contact which accounts for approximately 396,390 cases, Heterosexual contact (297,292), Injecting drug users (IDUs) (237,834), and other routes with 59,458 cases in 2020 in the US.
The age-specific data revealed that the highest number of HIV-1 people affected with was found in the age group of 30-39 years followed by patients of age group 40-49 years (second-highest). In comparison, they are relatively less common in 13-19 years and <13 years.
In EU-5, France reported the highest diagnosed prevalent cases of HIV-1 with 153,253 cases in 2020, followed by Spain (127,233), Italy (116,573), UK (100,633), and Germany (82,081) in 2020.
In 2020, Japan had 26,870 diagnosed prevalent cases of HIV-1. These cases are expected to increase by 2030 at a CAGR of 2.61%.

HIV-1 Epidemiology

The epidemiology segment also provides the HIV-1 epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

HIV-1 Drug Chapters

The drug chapter segment of the HIV-1 report encloses the detailed analysis of HIV-1 marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the HIV-1 clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

HIV-1 Marketed Drugs

Pifeltro (Doravirine): Merck Sharp & Dohme Corp

Pifeltro, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.

Products detail in the report…

Isentress/Isentress HD (Raltegravir): Merck

Isentress was the first Integrase strand transfer inhibitor (InstIs) developed for the treatment of HIV-1 infection. Isentress is recommended regimen option in combination with other antiretroviral agents as first-line therapy in treatment-naive HIV-1 infected adults. Isentress chewable tablets and oral suspension, each in combination therapy, are approved to treat pediatric patients aged at least 4 weeks and weighing less than 20 kg. Isentress HD is a 1200 mg once-daily dose of the company’s integrase inhibitor, Isentress (raltegravir), to be administered orally as two 600 mg film-coated tablets.

Products detail in the report…

Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate): Gilead Sciences, Inc

Truvada is an oral formulation indicated in combination with other antiretroviral agents to treat HIV-1 infection in certain patients. It is a fixed-dose combination of Gilead’s antiretroviral medications: TDF and emtricitabine (FTC). Truvada is also approved by the FDA for a PrEP (pre-exposure prophylaxis) indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.

Products detail in the report…

Dovato (Dolutegravir and Lamivudine): ViiV Healthcare

Dovato is a once-daily, single-pill, two-drug regimen (2DR) that combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, 300 mg).

Products detail in the report…

Cabenuva (Vocabria/Rekambys Injection): ViiV Healthcare

Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir (brand name: Vocabria) or rilpivirine (injectable brand name: Rekambys). Cabenuva is administered as two intramuscular injections (cabotegravir and rilpivirine) in the buttocks during the same visit at a specialist clinic by a healthcare professional.

Products detail in the report…

List to be continued in the report…

HIV-1 Emerging Drugs

Lenacapavir (GS-6207): Gilead Sciences

Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development to treat and prevent HIV-1 infection. Lenacapavir’s multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for developing long-acting therapy options for people living with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle and has no known cross-resistance to other existing drug classes.

Products detail in the report…

GSK3640254 (GSK’254): GlaxoSmithKline/ViiV Healthcare

GSK3640254 is a next-generation HIV-1 Maturation Inhibitor (MI) that acts during the last step of the HIV lifecycle. GSK3640254 binds to HIV-1 Gag, inhibiting the final protease-mediated cleavage event between capsid (CA) protein p24 and spacer peptide 1 (SP1) within the Gag polyprotein. Prevention of Gag polyprotein separation to its component proteins p24/CA and SP1 results in the release of immature, noninfectious virions. The drug is currently being investigated in the Phase II trial.

Products detail in the report…

MK-8591A (Islatravir/doravirine; DOR/ISL): Merck & Co., Inc.

Merck Sharp & Dohme Corp. is evaluating MK-8591A (islatravir/doravirine; DOR/ISL), a combination of islatravir – the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) – and doravirine (Pifeltro), for the treatment of HIV-1 infection. The combinational drug is currently being evaluated in a Phase III clinical study for the treatment and prevention of HIV.

Products detail in the report…

List to be continued in the report…

HIV-1 Market Outlook

The United States contributes to the major share of the HIV-1 market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan.

There are many medicines available for HIV regimens. Approved antiretroviral (ARV) HIV drugs are divided into seven drug classes based on how each drug interferes with the HIV life cycle: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and integrase strand transfer inhibitors (INSTIs). Fusion inhibitors, CCR5 antagonists, and post-attachment inhibitors can also be known as entry inhibitors as they prevent the entry of HIV into the CD4 cells.

The choice of an HIV regimen depends on a person’s individual needs. When choosing an HIV regimen, people with HIV and their health care providers consider many factors, including possible side effects of HIV medicines and potential drug interactions.

The current antiretroviral drugs, including newer classes, can be partially or fully inactive because of the emergence of drug-resistant virus strains. Now oral pre-exposure prophylaxis (PrEP) is recommended in the risk group population, there are high chances of resistance if patients taking PrEP become infected. This could reduce treatment options due to the overlapping resistance profiles between antiretroviral drugs used for both PrEP and treatment. Truvada and Descovy are currently approved as oral therapies for PrEP, and new therapies, such as islatravir, are in a clinical trial.

Initially, patients have to take multiple drug products of different active pharmaceutical ingredients (API) daily. To solve the problems with MTR, single treatment regimens (STR) have emerged. STR combines two or more antiretroviral drugs from more than one drug class in a single pill. The first STR, a fixed-dose combination of three drugs in one tablet called Atripla, was introduced in 2006. There are some common trends observed in the HIV-1 treatment market. The first one is the emergence of tenofovir alafenamide (TAF)-based regimens over tenofovir disoproxil fumarate (TDF) - based regimens. The main concern with TAD is that it can cause renal toxicity, decreased bone mineral density (BMD), and increased bone turnover markers. Due to this, physicians now prefer TAF-based regimens, and this preference has affected the market of TDF-based regimens. The second trend is the rise of integrase/NRTI triple therapies. The growth of INSTI is affecting the market of PIs and NRTIs.

The HIV-1 treatment market is expected to show steady growth in the coming years. However, it might get affected due to the wave of patent expiry of some of the products. According to DelveInsight, HIV-1 7MM is expected to change in the study period 2018–2030.

Key Findings
The market size of HIV-1 in seven major markets was USD 22,663 million in 2020, which is further expected to increase by 2030 at a Compound Annual Growth Rate (CAGR) of 4.60% for the study period (2018–2030).
The total market size includes the market size of therapies for treatment naïve or experienced patients, multiple drug resistance (MDR), and pre-exposure prophylaxis. The market size of these groups of therapies was USD 20,947 million, USD 60 million, and USD 1,656 million, respectively in 2020, in the 7MM.
Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of HIV-1.
Upcoming therapies for treatment naïve or experienced patients such as GSK3640254, Lenacapavir + ARV, MK-8591A (Islatravir/doravirine), and MK8591B (islatravir + MK-8507), for multiple drug resistance (MDR) treatment [Rukobia + OBR, MK-8591A (Islatravir/doravirine), Lenacapavir + OBR, and Vyrologix (leronlimab) + OBR] and for PrEP [Lenacapavir, Islatravir, and Vocabria (Cabotegravir LA)] have the potential to create a significant positive shift in the HIV-1 market size.
The United States accounts for the largest market size of HIV-1, with USD 19,153 million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Among the EU5 countries, France had the highest market size with USD 865 million in 2020, while Germany had the lowest market size of HIV-1 with USD 457 million in 2020.
Japan consistently captured lowest market size among 7MM countries, i.e., USD 216 million in 2020.

The United States Market Outlook

This section provides the total HIV-1 market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total HIV-1 market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total HIV-1 market size and market size by therapies in Japan are provided.

HIV-1 Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the HIV-1 market or expected to get launched in the market during the study period 2018–2030. The analysis covers HIV-1 market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

HIV-1 Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for HIV-1 emerging therapies.

Reimbursement Scenario in HIV-1

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the HIV-1 market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of HIV-1, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
Comprehensive insight has been provided into the HIV-1 epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for HIV-1 is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the HIV-1 market; historical and forecasted is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM HIV-1 market.

Report Highlights
The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the HIV-1 market.
The companies and academics are working to assess challenges and seek opportunities that could influence HIV-1 R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for HIV-1. Launch of emerging therapies will significantly impact the HIV-1 market.
Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

HIV-1 Report Insights
Patient Population
Therapeutic Approaches
HIV-1 Pipeline Analysis
HIV-1 Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

HIV-1 Report Key Strengths
10-Years Forecast
7MM Coverage
HIV-1 Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

HIV-1 Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
SWOT analysis

Key Questions

Market Insights:
What was the HIV-1 market share (%) distribution in 2018 and how it would look like in 2030?
What would be the HIV-1 total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
What are the key findings pertaining to the market across the 7MM and which country will have the largest HIV-1 market size during the forecast period (2021–2030)?
At what CAGR, the HIV-1 market is expected to grow at the 7MM level during the forecast period (2021–2030)?
What would be the HIV-1 market outlook across the 7MM during the forecast period (2021–2030)?
What would be the HIV-1 market growth till 2030 and what will be the resultant market size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
What is the disease risk, burden and unmet needs of HIV-1?
What is the historical HIV-1 patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of HIV-1 at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HIV-1?
Out of the above-mentioned countries, which country would have the highest incident population of HIV-1 during the forecast period (2021–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
What are the current options for the treatment of HIV-1 along with the approved therapy?
What are the current treatment guidelines for the treatment of HIV-1 in the US and Europe?
What are the HIV-1 marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of HIV-1?
How many emerging therapies are in the mid-stage and late stages of development for the treatment of HIV-1?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HIV-1 therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for HIV-1 and their status?
What are the key designations that have been granted for the emerging therapies for HIV-1?
What are the 7MM historical and forecasted market of HIV-1?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the HIV-1.
To understand the future market competition in the HIV-1 market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for HIV-1 in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the HIV-1 market.
To understand the future market competition in the HIV-1 market.


1 Key Insights
2 Report Introduction
3 Human immunodeficiency virus 1 (HIV-1) Market Overview at a Glance
3.1. Market Share (%) Distribution of HIV-1 by therapies in 2018
3.2. Market Share (%) Distribution of HIV-1 by therapies in 2030
4 Human immunodeficiency virus 1 Market: Future Perspective
5 Executive Summary of HIV-1
6 Key Events
7 Disease Background and Overview
7.1. Introduction
7.2. Types of Human Immunodeficiency Virus (HIV)
7.2.1. HIV-1
7.2.1.1. Structure of HIV-1
7.2.1.2. Genetic Diversity in HIV-1
7.2.2. HIV-2
7.3. Lifecycle of HIV
7.4. Stages and Symptoms of HIV infection
7.5. Causes/Transmission of HIV infection
7.6. Pathogenesis of HIV-1
7.6.1. HIV Transmission and Early Infection
7.6.2. The Founder Virus
7.6.3. Early Events in Replication
7.6.4. HIV-1 Target Cells
7.6.4.1. T-cell Subsets
7.6.4.2. Monocytes, Macrophages, and NK Cells
7.6.5. Dissemination and Persistence in Target Tissues
7.6.5.1. Lymph Nodes and blood
7.6.5.2. Gut-associated Lymphoid Tissue (GALT)
7.6.5.3. CNS
7.6.5.4. Genital Tract
7.6.5.5. Other Cell and Tissue Types
7.6.6. Mechanism of Cell Killing
7.7. HIV-1 Diagnosis
7.7.1. Types of HIV-1 Diagnosis Tests
7.7.1.1. HIV Antibody Tests
7.7.1.2. Antigen/Antibody Test
7.7.1.3. Nucleic Acid Tests (NAT)
7.7.2. Generations of HIV tests
7.7.3. HIV-1 Diagnosis Algorithm
7.7.4. Diagnostic Guidelines and Recommendations
7.7.4.1. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings
7.7.4.2. British HIV Association/British Association for Sexual Health and HIV/British Infection Association Adult HIV Testing Guidelines 2020
7.8. Treatment and Management
7.8.1. Anti-RetroViral Therapy drug classes
7.8.2. HIV drug resistance
7.8.3. Treatment Algorithm
7.8.4. Treatment Guidelines
7.8.4.1. WHO Guidelines
7.8.4.2. US Guidelines
7.8.4.3. European AIDS Clinical Society (EACS) Guidelines
8 Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
8.3.1. United States
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. United Kingdom
8.3.7. Japan
8.4. Prevalence of HIV in the 7MM
8.5. Diagnosed Prevalence of HIV in the 7MM
8.6. The United States
8.6.1. Prevalence of HIV in the United States
8.6.2. Diagnosed Prevalence of HIV in the United States
8.6.3. Type-specific Diagnosed Prevalence of HIV in the United States
8.6.4. Gender-specific Diagnosed Prevalence of HIV-1 in the United States
8.6.5. Diagnosed Prevalence of HIV-1 by route of transmission in the United States
8.6.6. Age-specific Diagnosed Prevalence of HIV-1 in the United States
8.7. EU-5
8.7.1. Prevalence of HIV in EU-5
8.7.2. Diagnosed Prevalence of HIV in EU-5
8.7.3. Type-specific Diagnosed Prevalence of HIV in EU-5
8.7.4. Gender-specific Diagnosed Prevalence of HIV-1 in EU-5
8.7.5. Diagnosed Prevalence of HIV-1 by route of transmission in EU-5
8.7.6. Age-specific Diagnosed Prevalence of HIV-1 in EU-5
8.8. Japan
8.8.1. Prevalence of HIV in Japan
8.8.2. Diagnosed Prevalence of HIV in Japan
8.8.3. Type-specific Diagnosed Prevalence of HIV in Japan
8.8.4. Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan
8.8.5. Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan
8.8.6. Age-specific Diagnosed Prevalence of HIV1 in Japan
9 Patient Journey
10 Marketed Therapies
10.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
10.1.1. Pifeltro (Doravirine): Merck Sharp & Dohme Corp
10.1.1.1. Product Description
10.1.1.2. Regulatory Milestones
10.1.1.3. Other Developmental activities
10.1.1.4. Clinical Development
10.1.1.5. Clinical Trials Information
10.1.1.6. Safety and Efficacy
10.1.1.7. Product Profile
10.2. Integrase strand transfer inhibitors (INSTIs)
10.2.1. Isentress/Isentress HD (Raltegravir): Merck
10.2.1.1. Product Description
10.2.1.2. Regulatory Milestones
10.2.1.3. Other Developmental activities
10.2.1.4. Clinical Development
10.2.1.5. Clinical Trials Information
10.2.1.6. Safety and Efficacy
10.2.1.7. Product Profile
10.2.2. Tivicay/Tivicay PD: ViiV Healthcare
10.2.2.1. Product Description
10.2.2.2. Regulatory Milestones
10.2.2.3. Other Developmental activities
10.2.2.4. Clinical Development
10.2.2.5. Clinical Trials Information
10.2.2.6. Safety and Efficacy
10.2.2.7. Product Profile
10.2.3. Vocabria (cabotegravir): ViiV Healthcare
10.2.3.1. Product Description
10.2.3.2. Regulatory Milestones
10.2.3.3. Other Developmental activities
10.2.3.4. Clinical Development
10.2.3.5. Clinical Trials Information
10.2.3.6. Safety and Efficacy
10.2.3.7. Product Profile
10.2.3.8. Analyst Commentary
10.3. Protease inhibitors/Protease inhibitors
10.3.1. CYP3A inhibitor (Pharmacokinetic Enhancers)
10.3.2. NRTI + NRTI Approved for the Treatment of HIV-1
10.3.3. Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate): Gilead Sciences, Inc.
10.3.3.1. Product Description
10.3.3.2. Regulatory Milestones
10.3.3.3. Other Developmental activities
10.3.3.4. Clinical Development
10.3.3.5. Clinical Trials Information
10.3.3.6. Safety and Efficacy
10.3.3.7. Product Profile
10.3.4. Descovy (Emtricitabine and Tenofovir Alafenamide): Gilead Sciences, Inc.
10.3.4.1. Product Description
10.3.4.2. Regulatory Milestones
10.3.4.3. Other Developmental activities
10.3.4.4. Clinical Development
10.3.4.5. Clinical Trials Information
10.3.4.6. Safety and Efficacy
10.3.4.7. Product Profile
10.4. INSTI + NRTI approved for the treatment of HIV-1
10.4.1. Dovato (Dolutegravir and Lamivudine): ViiV Healthcare
10.4.1.1. Product Description
10.4.1.2. Regulatory Milestones
10.4.1.3. Other Developmental activities
10.4.1.4. Clinical Development
10.4.1.5. Clinical Trials Information
10.4.1.6. Safety and Efficacy
10.4.1.7. Product Profile
10.5. INSTI plus NNRTI approved for the treatment of HIV-1
10.5.1. Juluca (dolutegravir and rilpivirine): ViiV Healthcare/Janssen Pharmaceuticals
10.5.1.1. Product Description
10.5.1.2. Regulatory Milestones
10.5.1.3. Other Developmental activities
10.5.1.4. Clinical Development
10.5.1.5. Clinical Trials Information
10.5.1.6. Safety and Efficacy
10.5.1.7. Product Profile
10.5.2. Cabenuva (Vocabria/Rekambys Injection): ViiV Healthcare
10.5.2.1. Product Description
10.5.2.2. Regulatory Milestones
10.5.2.3. Other Developmental activities
10.5.2.4. Clinical Development
10.5.2.5. Clinical Trials Information
10.5.2.6. Safety and Efficacy
10.5.2.7. Product Profile
10.5.2.8. Analyst’s Views
10.6. Protease inhibitor + CYP3A inhibitor + NRTI + NRTI approved for the treatment of HIV-1
10.6.1. Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide): Janssen Pharmaceutical Companies
10.6.1.1. Product Description
10.6.1.2. Regulatory Milestones
10.6.1.3. Other Developmental activities
10.6.1.4. Clinical Development
10.6.1.5. Clinical Trials Information
10.6.1.6. Safety and Efficacy
10.6.1.7. Product Profile
10.7. INSTI + CYP3A inhibitor + (NRTI + NRTI), Approved for the Treatment of HIV-1
10.7.1. Genvoya: Gilead Sciences
10.7.1.1. Drug Description
10.7.1.2. Regulatory Milestones
10.7.1.3. Other Development Activities
10.7.1.4. Clinical Development
10.7.1.5. Clinical Trials Information
10.7.1.6. Safety and Efficacy
10.7.1.7. Product Profile
10.7.2. Stribild: Gilead Sciences
10.7.2.1. Drug Description
10.7.2.2. Regulatory Milestones
10.7.2.3. Other Development Activities
10.7.2.4. Clinical Development
10.7.2.5. Clinical Trials Information
10.7.2.6. Safety and Efficacy
10.7.2.7. Product Profile
10.8. NNRTI + (NRTI + NRTI), Approved for the Treatment of HIV-1
10.8.1. Delstrigo: Merck Sharp & Dohme Corp
10.8.1.1. Drug Description
10.8.1.2. Regulatory Milestones
10.8.1.3. Other Development Activities
10.8.1.4. Clinical Development
10.8.1.5. Clinical Trials Information
10.8.1.6. Safety and Efficacy
10.8.1.7. Product Profile
10.8.2. Atripla: Gilead Sciences
10.8.2.1. Drug Description
10.8.2.2. Regulatory Milestones
10.8.2.3. Other Development Activities
10.8.2.4. Clinical Development
10.8.2.5. Clinical Trials Information
10.8.2.6. Safety and Efficacy
10.8.2.7. Product Profile
10.8.3. Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide): Gilead Sciences/Janssen Pharmaceutical KK
10.8.3.1. Product Description
10.8.3.2. Regulatory Milestones
10.8.3.3. Other Developmental activities
10.8.3.4. Clinical Development
10.8.3.5. Clinical Trials Information
10.8.3.6. Safety and Efficacy
10.8.3.7. Product Profile
10.8.4. Complera/Eviplera (Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate): Gilead Sciences, Inc./Janssen Pharmaceutical KK
10.8.4.1. Product Description
10.8.4.2. Regulatory Milestones
10.8.4.3. Other Developmental activities
10.8.4.4. Clinical Development
10.8.4.5. Safety and Efficacy
10.8.4.6. Product Profile
10.8.5. Symfi Lo/Symfi (Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate): Mylan Laboratories Limited
10.8.5.1. Drug Description
10.8.5.2. Regulatory Milestones
10.8.5.3. Clinical Development
10.8.5.4. Clinical Trials Information
10.8.5.5. Safety and Efficacy
10.8.5.6. Product Profile
10.9. Protease Inhibitors (PIs) approved for the treatment of HIV-1
10.10. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) approved for the treatment of HIV-1
10.10.1. Viread (tenofovir): Gilead Science
10.10.1.1. Product Description
10.10.1.2. Regulatory Milestones
10.10.1.3. Other Developmental activities
10.10.1.4. Clinical Development
10.10.1.5. Clinical Trials Information
10.10.1.6. Safety and Efficacy
10.10.1.7. Product Profile
10.10.1.8. Analyst Commentary
10.11. INSTI plus NRTI plus NRTI approved for the treatment of HIV-1
10.11.1. Biktarvy: Gilead Sciences
10.11.1.1. Product Description
10.11.1.2. Regulatory Milestones
10.11.1.3. Other Developmental activities
10.11.1.4. Clinical Development
10.11.1.5. Clinical Trials Information
10.11.1.6. Safety and Efficacy
10.11.1.7. Product Profile
10.11.1.8. Analyst Commentary
10.11.2. Triumeq/ Tivicay (abacavir, dolutegravir, and lamivudine): ViiV Healthcare
10.11.2.1. Product Description
10.11.2.2. Regulatory Milestones
10.11.2.3. Other Developmental activities
10.11.2.4. Clinical Development
10.11.2.5. Clinical Trials Information
10.11.2.6. Safety and Efficacy
10.11.2.7. Product Profile
10.11.2.8. Analyst Commentary
10.12. Protease inhibitor plus CYP3A inhibitor approved for the treatment of HIV-1
10.13. Entry Inhibitors Approved for the Treatment of HIV-1
10.13.1. Rukobia: ViiV Healthcare
10.13.1.1. Product Description
10.13.1.2. Regulatory Milestones
10.13.1.3. Other Developmental activities
10.13.1.4. Clinical Development
10.13.1.5. Clinical Trials Information
10.13.1.6. Safety and Efficacy
10.13.1.7. Product Profile
10.13.1.8. Analyst Commentary
10.13.2. Trogarzo (Ibalizumab-uiyk): TaiMed Biologics Inc. / Theratechnologies Inc.
10.13.2.1. Product Description
10.13.2.2. Regulatory Milestones
10.13.2.3. Other Developmental activities
10.13.2.4. Clinical Development
10.13.2.5. Clinical Trials Information
10.13.2.6. Safety and Efficacy
10.13.2.7. Product Profile
11 Emerging Drugs
11.1. Key Cross Competition
11.1.1. Lenacapavir (GS-6207): Gilead Sciences
11.1.1.1. Product Description
11.1.1.2. Other Developmental activities
11.1.1.3. Clinical Development
11.1.1.4. Clinical Trials Information
11.1.1.5. Safety and Efficacy
11.1.1.6. Product Profile
11.1.1.7. Analysts’ Views
11.1.2. ALVAC-HIV (vCP2438)/HVTN 702: Sanofi/GlaxoSmithKline/National Institute of Allergy and Infectious Diseases
11.1.2.1. Product Description
11.1.2.2. Clinical Development
11.1.2.3. Clinical Trials Information
11.1.2.4. Safety and Efficacy
11.1.2.5. Product Profile
11.1.3. GSK3640254 (GSK’254): GlaxoSmithKline/ViiV Healthcare
11.1.3.1. Product Description
11.1.3.2. Clinical Development
11.1.3.3. Clinical Trials Information
11.1.3.4. Safety and Efficacy
11.1.3.5. Product Profile
11.1.3.6. Analysts’ Views
11.1.4. UB-421: United Biopharma
11.1.4.1. Product Description
11.1.4.2. Other Developmental activities
11.1.4.3. Clinical Development
11.1.4.4. Clinical Trials Information
11.1.4.5. Safety and Efficacy
11.1.4.6. Product Profile
11.1.4.7. Analysts’ Views
11.1.5. MK-8591A (Islatravir/doravirine; DOR/ISL): Merck & Co., Inc.
11.1.5.1. Product Description
11.1.5.2. Other Developmental Activities
11.1.5.3. Clinical Development
11.1.5.4. Clinical Trials Information
11.1.5.5. Safety and Efficacy
11.1.5.6. Product Profile
11.1.5.7. Analyst’s View
11.1.6. Ad26.Mos4.HIV/VAC89220: Janssen Pharmaceuticals
11.1.6.1. Product Description
11.1.6.2. Other Developmental Activities
11.1.6.3. Clinical Development
11.1.6.4. Clinical Trials Information
11.1.6.5. Safety and Efficacy
11.1.6.6. Product Profile
11.1.6.7. Analysts’ Views
11.1.7. Vyrologix (leronlimab-PRO 140): CytoDyn
11.1.7.1. Product Description
11.1.7.2. Other Developmental Activities
11.1.7.3. Clinical Development
11.1.7.4. Clinical Trials Information
11.1.7.5. Safety and Efficacy
11.1.7.6. Product Profile
11.1.7.7. Analysts’ Views
11.1.8. Albuvirtide: Frontier Biotechnologies
11.1.8.1. Product Description
11.1.8.2. Other Developmental Activities
11.1.8.3. Clinical Development
11.1.8.4. Clinical Trials Information
11.1.8.5. Safety and Efficacy
11.1.8.6. Product Profile
11.1.8.7. Analysts’ Views
11.1.9. HTI Vaccine (ChAdOx1.HTI and MVA.HTI): Aelix Therapeutics
11.1.9.1. Product Description
11.1.9.2. Other Developmental Activities
11.1.9.3. Clinical Development
11.1.9.4. Clinical Trials Information
11.1.9.5. Safety and Efficacy
11.1.9.6. Product Profile
11.1.9.7. Analyst commentary
12 Human Immunodeficiency Virus 1 (HIV-1): Seven Major Market Analysis
12.1. Key Findings
12.2. Methodology of Human Immunodeficiency Virus 1 (HIV-1) Market
12.2.1. Methodology for Treatment naïve and experienced and MDR HIV-1 population
12.2.2. Methodology for Pre-exposure Prophylaxis of HIV-1
12.3. Total Market Size of HIV-1 in the 7MM
12.4. Market Size of HIV-1 by Therapies in 7MM
12.4.1. Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients
12.4.2. Market Size of HIV-1 Therapies for Multiple Drug Resistance
12.4.3. Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis
12.4.4. Emerging Drug Analysis
12.4.5. Key Market Forecast Assumptions
12.4.6. Attribute Analysis
12.4.7. Market Outlook
12.5. Market Size of HIV-1 in the United States
12.5.1. Total Market Size of HIV-1 in the United States
12.5.2. Market Size of HIV-1 by Therapies in the United States
12.5.2.1. Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients
12.5.2.2. Market Size of HIV-1 Therapies for Multiple Drug Resistance
12.5.2.3. Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis
12.6. Market Size of HIV-1 in the EU-5
12.6.1. Total Market Size of HIV-1 in the EU-5
12.6.2. Market Size of HIV-1 by Therapies in the EU-5
12.6.2.1. Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients
12.6.2.2. Market Size of HIV-1 Therapies for Multiple Drug Resistance
12.6.2.3. Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis
12.7. Market Size of HIV-1 in Japan
12.7.1. Total Market Size of HIV-1 in Japan
12.7.2. Market Size of HIV-1 by Therapies in Japan
12.7.2.1. Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients
12.7.2.2. Market Size of HIV-1 Therapies for Multiple Drug Resistance
12.7.2.3. Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis
13 KOL Views
14 Market Drivers
15 Market Barriers
16 SWOT Analysis
17 Unmet Needs
18 Reimbursement and access of HIV-1 therapies
18.1. United States
18.1.1. The Affordable Care Act (ACA), how access changed overtime for the HIV patients
18.1.2. Market access
18.1.2.1. Private Resources
18.1.2.2. Federal Resources
18.1.3. Reimbursement
18.1.3.1. Reimbursement of drugs by Merck & Co
18.1.3.2. Reimbursement of drugs by Gilead
18.1.3.3. Reimbursement of HIV drugs by ViiV Hearlthcare
18.2. Europe
18.2.1. Market Access and Reimbursement in Europe
18.2.1.1. PrEP Access in Europe
18.3. Japan
19 Appendix
19.1. Bibliography
19.1.1. Report Methodology
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
Table 1: Summary of HIV-1 Market and Epidemiology (2018–2030)
Table 2: Key Events
Table 3: Difference Between HIV-1 and HIV-2
Table 4: US FDA approved antiretroviral Classes and drugs
Table 5: WHO followed the following principles in developing the simplified tables
Table 6: Dosages of ARV drugs for adults and adolescents
Table 7: Simplified dosing of child-friendly fixed-dose solid formulations for twice-daily dosing for infants and children 4 weeks and older
Table 8: Simplified dosing of child-friendly solid formulations for once-daily dosing for infants and children 4 weeks and older
Table 9: Simplified dosing of child-friendly solid and oral liquid formulations for twice-daily dosing for infants and children 4 weeks of age and older (1)
Table 10: Simplified dosing of child-friendly solid and oral liquid formulations for twice-daily dosing for infants and children 4 weeks of age and older (2)
Table 11: Drug dosing of liquid formulations for infants younger than 4 weeks of age
Table 12: ARV drug dose adjustment for children receiving rifampicin-containing TB treatment
Table 13: Simplified age-based ARV drug dosing for administering enhanced and prolonged postnatal prophylaxis
Table 14: Recommended Oral PrEP Medications
Table 15: Summary of recommendations for PrEP Medications
Table 16: CDC’s recommendations for the use of antiretroviral agents in adults and adolescents with HIV
Table 17: Recommended regimens
Table 18: Prevalence of HIV among 7MM during 2010 and 2020
Table 19: Incidence of HIV among 7MM during 2010 and 2020
Table 20: Coverage of people receiving ART (all ages) among 7MM during 2010 and 2020
Table 21: Prevalence of HIV in the 7MM (2018–2030)
Table 22: Diagnosed Prevalence of HIV in the 7MM (2018–2030)
Table 23: Prevalence of HIV in the United States (2018–2030)
Table 24: Diagnosed Prevalence of HIV in the United States (2018–2030)
Table 25: Type-specific Diagnosed Prevalence of HIV in the United States (2018–2030)
Table 26: Gender-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)
Table 27: Diagnosed Prevalence of HIV-1 by route of transmission in the US (2018–2030)
Table 28: Age-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)
Table 29: Prevalence of HIV in EU-5 (2018–2030)
Table 30: Diagnosed Prevalence of HIV in EU-5 (2018–2030)
Table 31: Type-specific Diagnosed Prevalence of HIV in EU-5 (2018–2030)
Table 32: Gender-specific Diagnosed Prevalent Cases of HIV1 in EU-5 (2018–2030)
Table 33: Diagnosed Prevalence of HIV-1 by route of transmission in EU-5 (2018–2030)
Table 34: Age-specific Diagnosed Prevalence of HIV-1 in EU5 (2018–2030)
Table 35: Prevalence of HIV in Japan (2018–2030)
Table 36: Diagnosed Prevalence of HIV in Japan (2018–2030)
Table 37: Type-specific Diagnosed Prevalence of HIV in Japan (2018–2030)
Table 38: Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan (2018–2030)
Table 39: Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan (2018–2030)
Table 40: Age-specific Diagnosed Prevalence of HIV1 in Japan (2018–2030)
Table 41: NNRTIs approved for the treatment of HIV-1
Table 42: Pifeltro, Clinical Trial Description, 2021
Table 43: INSTIs approved for the treatment of HIV-1
Table 44: Isentress/Isentress HD, Clinical Trial Description, 2021
Table 45: Dosing Recommendations
Table 46: Tivicay and Tivicay PD, Clinical Trial Description, 2021
Table 47: Vocabria, Clinical Trial Description, 2021
Table 48: Virologic Outcomes of Randomized Treatment in FLAIR and ATLAS Trials at Week 48
Table 49: The Proportion of Subjects in FLAIR and ATLAS Trials with Plasma HIV-1 RNA ≥50 copies/mL at Week 48 for Key Baseline Factors
Table 50: Protease inhibitors/Protease inhibitors approved for the treatment of HIV-1
Table 51: CYP3A inhibitor approved for the treatment of HIV-1
Table 52: NRTI + NRTI Approved for the Treatment of HIV-1
Table 53: Truvada, Clinical Trial Description, 2021
Table 54: Trials Conducted with Truvada for HIV-1 Treatment and HIV-1 PrEP
Table 55: Descovy, Clinical Trial Description, 2021
Table 56: INSTI + NRTI approved for the treatment of HIV-1
Table 57: Dovato, Clinical Trial Description, 2021
Table 58: INSTI plus NNRTI approved for the treatment of HIV-1
Table 59: Juluca, Clinical Trial Description, 2021
Table 60: Cabenuva, Clinical Trial Description, 2021
Table 61: Protease inhibitor + CYP3A inhibitor + NRTI + NRTI approved for the treatment of HIV-1
Table 62: Symtuza, Clinical Trial Description, 2021
Table 63: INSTI + CYP3A inhibitor + (NRTI + NRTI), Approved for the Treatment of HIV-1
Table 64: Genvoya, Clinical Trial Description, 2021
Table 65: Stribild, Clinical Trial Description, 2021
Table 66: NNRTI + (NRTI + NRTI), Approved for the Treatment of HIV-1
Table 67: Delstrigo, Clinical Trial Description, 2021
Table 68: Atripla, Clinical Trial Description, 2021
Table 69: Odefsey, Clinical Trial Description, 2021
Table 70: Complera/Eviplera, Clinical Trial Description, 2021
Table 71: Symfi Lo , Clinical Trial Description, 2021
Table 72: Recommended Dosing for Patients 2 Years and Older and Weighing At Least 17 kg Using Viread Tablets
Table 73: Dosing for Patients 2 Years and Older Weighing At Least 10 kg Using Viread oral powder
Table 74: Viread, Clinical Trial Description, 2021
Table 75: Outcomes of Randomized Treatment (Trial 907)
Table 76: (INSTI + NRTI + NRTI) approved for the treatment of HIV-1
Table 77: Biktarvy, Clinical Trial Description, 2021
Table 78: Triumeq, Clinical Trial Description, 2021
Table 79: Rukobia, Clinical Trial Description, 2021
Table 80: Trogarzo, Clinical Trial Description, 2021
Table 81: Comparison of emerging drugs under development (Phase III)
Table 82: Comparison of emerging drugs under development (Phase II/III)
Table 83: Comparison of emerging drugs under development (Phase II)
Table 84: Comparison of emerging drugs under development (Early Phase) (1)
Table 85: Comparison of emerging drugs under development (Early Phase) (2)
Table 86: Lenacapavir, Clinical Trial Description, 2021
Table 87: ALVAC-HIV, Clinical Trial Description, 2021
Table 88: GSK3640254, Clinical Trial Description, 2021
Table 89: UB-421, Clinical Trial Description, 2021
Table 90: MK-8591A, Clinical Trial Description, 2021
Table 91: VAC89220, Clinical Trial Description, 2021
Table 92: PRO140, Clinical Trial Description, 2021
Table 93: Albuvirtide, Clinical Trial Description, 2021
Table 94: HTI Vaccine (ChAdOx1.HTI and MVA.HTI), Clinical Trial Description, 2021
Table 95: Market Size of HIV-1 in the 7MM, in USD Million (2018–2030)
Table 96: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in the 7MM, in USD Million (2018–2030)
Table 97: Market Size of HIV-1 Therapies for Multiple Drug Resistance in the 7MM, in USD Million (2018–2030)
Table 98: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in the US, in USD Million (2018–2030)
Table 99: Key Market Forecast Assumptions for GSK3640254
Table 100: Key Market Forecast Assumptions for Lenacapavir + ARV
Table 101: Key Market Forecast Assumptions for MK-8591A (Islatravir/doravirine)
Table 102: Key Market Forecast Assumptions for MK8591B (Islatravir + MK-8507)
Table 103: Key Market Forecast Assumptions for Rukobia + OBR
Table 104: Key Market Forecast Assumptions for MK-8591A (Islatravir/doravirine)
Table 105: Key Market Forecast Assumptions for Lenacapavir + OBR
Table 106: Key Market Forecast Assumptions for Vyrologix (leronlimab) + OBR
Table 107: Key Market Forecast Assumptions for Lenacapavir
Table 108: Key Market Forecast Assumptions for Islatravir
Table 109: Key Market Forecast Assumptions for Vocabria (Cabotegravir LA)
Table 110: United States Market Size of HIV-1 in USD Million (2018–2030)
Table 111: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in the US in USD Million (2018–2030)
Table 112: Market Size of HIV-1 Therapies for Multiple Drug Resistance in the US, in USD Million (2018–2030)
Table 113: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in the US, in USD Million (2018–2030)
Table 114: EU-5 Market Size of HIV-1 in USD Million (2018–2030)
Table 115: Germany Market Size of HIV-1 in USD Million (2018–2030)
Figure 1: Structure of Human Immunodeficiency Virus (HIV)
Figure 2: HIV-1 Types and Subtypes
Figure 3: Structure of 9.8 kb HIV-1 Genome
Figure 4: Schematic of the HIV-1 Virion
Figure 5: Life Cycle of HIV
Figure 6: Stages of HIV Infection
Figure 7: Modes of HIV-1 Transmission
Figure 8: HIV Susceptible Cells
Figure 9: Time Course of a Typical HIV-1 Infection With the Appearance of Host Range Variants Late
Figure 10: Types of HIV-1 Diagnostic tests
Figure 11: HIV-1 Diagnostic algorithm
Figure 12: Antiretroviral Classes
Figure 13: Simplified algorithm for treatment eligibility (SLATE) algorithm
Figure 14: Algorithm for management of HIV during pregnancy
Figure 15: Prevalence of HIV in the 7MM (2018–2030)
Figure 16: Diagnosed Prevalence of HIV in the 7MM (2018–2030)
Figure 17: Prevalence of HIV in the United States (2018–2030)
Figure 18: Diagnosed Prevalence of HIV in the United States (2018–2030)
Figure 19: Type-specific Diagnosed Prevalence of HIV in the United States (2018–2030)
Figure 20: Gender-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)
Figure 21: Diagnosed Prevalence of HIV-1 by route of transmission in the US (2018–2030)
Figure 22: Age-specific Diagnosed Prevalence of HIV-1 in the US (2018–2030)
Figure 23: Prevalence of HIV in EU-5 (2018–2030)
Figure 24: Diagnosed Prevalence of HIV in EU-5 (2018–2030)
Figure 25: Type-specific Diagnosed Prevalence of HIV in EU-5 (2018–2030)
Figure 26: Gender-specific Diagnosed Prevalence of HIV-1 in EU-5 (2018–2030)
Figure 27: Diagnosed Prevalence of HIV-1 by route of transmission in EU-5 (2018–2030)
Figure 28: Age-specific Diagnosed Prevalence of HIV-1 in EU-5
Figure 29: Prevalence of HIV in Japan (2018–2030)
Figure 30: Diagnosed Prevalence of HIV in Japan (2018–2030)
Figure 31: Type-specific Diagnosed Prevalence of HIV in Japan (2018–2030)
Figure 32: Gender-specific Diagnosed Prevalent Cases of HIV1 in Japan (2018–2030)
Figure 33: Diagnosed Prevalent Cases of HIV-1 by route of transmission in Japan (2018–2030)
Figure 34: Age-specific Diagnosed Prevalence of HIV1 in Japan (2018–2030)
Figure 35: Market Size of HIV-1 in the 7MM, USD Million (2018–2030)
Figure 36: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in the 7MM, in USD Million (2018–2030)
Figure 37: Market Size of HIV-1 Therapies for Multiple Drug Resistance in the 7MM, in USD Million (2018–2030)
Figure 38: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in the 7MM, in USD Million (2018–2030)
Figure 39: Market Size of HIV-1 in the United States, USD Million (2018–2030)
Figure 40: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in the United States, in USD Million (2018–2030)
Figure 41: Market Size of HIV-1 Therapies for Multiple Drug Resistance in the US, in USD Million (2018–2030)
Figure 42: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in the US, in USD Million (2018–2030)
Figure 43: Market Size of HIV-1 in the EU-5, USD Million (2018–2030)
Figure 44: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in the EU-5, in USD Million (2018–2030)
Figure 45: Market Size of HIV-1 Therapies for Multiple Drug Resistance in the EU-5, in USD Million (2018–2030)
Figure 46: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in the EU-5, in USD Million (2018–2030)
Figure 47: Market Size of HIV-1 in Japan, USD Million (2018–2030)
Figure 48: Market Size of HIV-1 Therapies for Treatment Naïve or Experienced Patients in Japan, in USD Million (2018–2030)
Figure 49: Market Size of HIV-1 Therapies for Multiple Drug Resistance in Japan, in USD Million (2018–2030)
Figure 50: Market Size of HIV-1 Therapies for Pre-exposure Prophylaxis in Japan, in USD Million (2018–2030)
Figure 51: Market Drivers
Figure 52: Market Barriers
Figure 53:Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook